Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Business Insights | Expanding Applications of Personalized Medicine: Use of biomarkers in prognostic, predictive and pharmacogenetic tests in a targeted approach

Expanding Applications of Personalized Medicine: Use of biomarkers in prognostic, predictive and pharmacogenetic tests in a targeted approach

Personalized medicine is the tailoring of medical treatment to specific groups of patients, rather than to the population as a whole. Over the past decade, several significant advances in targeted therapies have improved the ability to treat certain cancers, the most notable early successes been trastuzumab in breast cancer and imatinib in chronic myelogenous leukaemia. Recently, several important breakthroughs have occurred, including the identification of a mechanism of resistance to EGFR monoclonal antibodies in colorectal cancer, which may be followed by further predictive tests leading to a reduction in the use of ineffective therapies. The number of drugs with pharmacogenomic recommendations in product labels is steadily increasing, widening the application of personalized medicine to individualize treatments beyond cancer. Although investment in personalized medicine is beginning to show valuable results, its integration into routine clinical practice has been slow and it currently does not impact the care of the vast majority of patients. To widen the benefits of personalized medicine over the next ten years, several obstacles need to be overcome, including increased regulatory burden, lack of reimbursement, demonstration of clinical utility and integration into drug development.

Published: August 2009 - Global.

Table of Contents
Price: $3,825.00 / €2,533.30

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions